TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27995531

Group type: COMPARATOR
Intervention: Subcutaneous IFN‐β‐1a 44 mcg three times a week (group 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous IFN‐β‐1a 44 mcg three times a week plus ethinyl estradiol 40 mcg and desogestrel 125 mcg (group 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous IFN‐β‐1a 44 mcg three times a week plus ethinyl estradiol 20 mcg and desogestrel 150 mcg (group 2)
Number of subjects: 0
Study: 25496007

Group type: EXPERIMENTAL
Intervention: Beclabuvir 75 mg plus pegIFN (180 μg) and RBV (1000 mg/day [<75 kg])
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Beclabuvir 150 mg plus pegIFN (180 μg) and RBV (1200 mg/day [≥ 75 kg])
Number of subjects: 39

Group type: COMPARATOR
Intervention: PegIFN/RBV alone
Number of subjects: 39
Study: 23979614

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (25 microgram every six hours for a Bishop score lower than 7)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Intravenous oxytocin (low dose regimen for a Bishop score equal to or more than 7)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Cervical ripening factors
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Cervical posterior angle
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Cervical length, Body Mass Index (BMI), and parity
Number of subjects: 101
Study: 20977367

Group type: EXPERIMENTAL
Intervention: Subconjunctival bevacizumab (7.5 mg total: 5 mg/0.2 mL on the day of surgery and 2.5 mg on the fourth day after surgery)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Balanced salt solution (0.2 mL at the end of surgery)
Number of subjects: 44
Study: 19242918

Group type: COMPARATOR
Intervention: 6-month, home-based exercise program (n=25)
Number of subjects: 125

Group type: COMPARATOR
Intervention: 6-month, supervised exercise intervention (n=37)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Usual care (n=25) for newly diagnosed survivors
Number of subjects: 125

Group type: COMPARATOR
Intervention: Usual care (n=38) for post-treatment survivors
Number of subjects: 125
Study: 16739538

Group type: EXPERIMENTAL
Intervention: Interactive multimedia tutorial
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group (took the tutorial before posttest)
Number of subjects: 174
Study: 15315114

Group type: EXPERIMENTAL
Intervention: Individualized formulas in long duration patients
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Individualized formulas in kidney failure patients
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Individualized formulas in liver failure patients
Number of subjects: 511
Study: 11264207

Group type: EXPERIMENTAL
Intervention: Home exercise programme delivered by trained nurses
Number of subjects: 450

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 450
Study: 9706364

Group type: EXPERIMENTAL
Intervention: Self-referred genetic counseling for breast-ovarian cancer risk
Number of subjects: 256
Study: 8586330

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Brachial plexus analgesia (group K)
Number of subjects: 80
Study: 2680140

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 5356

Group type: COMPARATOR
Intervention: Saline inoculations (Control)
Number of subjects: 5356
Study: 810719

Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Surgical therapy (urgent surgical coronary bypass)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Medical therapy and Surgical therapy
Number of subjects: 40
Study: 31005973

Group type: EXPERIMENTAL
Intervention: BCAA supplementation (20 g daily for 4 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-BCAA control (protein low in BCAAs for 4 weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-BCAA control
Number of subjects: 12
Study: 28891830

Group type: EXPERIMENTAL
Intervention: Restrictive fluid infusion (5 mL/kg/h lactated Ringer solution)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Liberal fluid infusion (30 mL/kg/h lactated Ringer solution)
Number of subjects: 100
Study: 25358078

Group type: EXPERIMENTAL
Intervention: 50 mcg of sublingual misoprostol
Number of subjects: 200

Group type: COMPARATOR
Intervention: 25 mcg of vaginal misoprostol
Number of subjects: 200
Study: 23435397

Group type: EXPERIMENTAL
Intervention: Symbiosal (NaCl + chitosan 3%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: NaCl
Number of subjects: 40
Study: 21375093

Group type: EXPERIMENTAL
Intervention: Subinguinal technique (5 ml of 1% mepivacaine)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Nerve-targeting technique (5 ml of 1% mepivacaine)
Number of subjects: 106
Study: 19690428

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy at a dose of 0.066 mg/kg body weight per day
Number of subjects: 135
Study: 17313535

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia multimedia intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: One-on-one patient education of routine nursing guide and pain management with pamphlet (Control)
Number of subjects: 60
Study: 15278758

Group type: EXPERIMENTAL
Intervention: 10 cc of 1% lignocaine + 40 mg of methylprednisolone for the first and second injections
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 10 cc of 1% lignocaine + 40 mg of methylprednisolone for the first injection and only 10 cc of 1% lignocaine for the second injection
Number of subjects: 48

Group type: COMPARATOR
Intervention: only 10 cc of 1% lignocaine for the first and second injections
Number of subjects: 48
Study: 11205135

Group type: EXPERIMENTAL
Intervention: Functional imaging (PET and SPECT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 18F‐dopa PET findings in transplantation trials
Number of subjects: 0
Study: 9011442

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 54
Study: 1600826

Group type: EXPERIMENTAL
Intervention: Alleged 'fast' team
Number of subjects: 128

Group type: COMPARATOR
Intervention: Alleged 'slow' team
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 5-year-old children
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 3-year-old children
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Gender differences
Number of subjects: 128
Study: 6385228

Group type: EXPERIMENTAL
Intervention: Intra-articular indoprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31961396

Group type: EXPERIMENTAL
Intervention: Bempedoic Acid added to maximally tolerated statins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo added to maximally tolerated statins
Number of subjects: 0
Study: 30431393

Group type: EXPERIMENTAL
Intervention: Theory‐based Patient portal e‐Learning Program (T‐PeP)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 272
Study: 28190797

Group type: EXPERIMENTAL
Intervention: 60 min physical exercise (PE) at school daily
Number of subjects: 445

Group type: COMPARATOR
Intervention: 2 units of 45-min PE weekly (control group)
Number of subjects: 445
Study: 27557301

Group type: EXPERIMENTAL
Intervention: Focused ultrasound thalamotomy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 76
Study: 25085230

Group type: EXPERIMENTAL
Intervention: Uncovered metallic stents (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Covered metallic stents (n=20)
Number of subjects: 40
Study: 22875557

Group type: EXPERIMENTAL
Intervention: Acupuncture plus conventional care
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Physiotherapy plus conventional care
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Acupuncture plus physiotherapy plus conventional care
Number of subjects: 274
Study: 19768295

Group type: EXPERIMENTAL
Intervention: Deep Breathing Exercises (DBE)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Incentive Spirometry (IS)
Number of subjects: 36
Study: 17341589

Group type: EXPERIMENTAL
Intervention: Skins compression garment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Adidas compression garment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Under Armour compression garment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no compression garment)
Number of subjects: 10
Study: 15807174

Group type: EXPERIMENTAL
Intervention: INF-alpha (5MU 3x per week during 4-6 months)
Number of subjects: 103

Group type: COMPARATOR
Intervention: lamivudine (100mg per day during 1-4 years)
Number of subjects: 103
Study: 11232683

Group type: EXPERIMENTAL
Intervention: EUS-guided celiac plexus block with 10 cc bupivacaine (0.25%) and 3 cc (40 mg) triamcinolone injected on each side of the celiac plexus.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: EUS-guided celiac plexus block
Number of subjects: 90
Study: 9648699

Group type: EXPERIMENTAL
Intervention: 0.5 ppm chlorine in filtered air
Number of subjects: 16

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 16
Study: 8270989

Group type: EXPERIMENTAL
Intervention: Etoposide at 20, 25, or 30 mg/m2/d infused continuously for 14 days (336 hours) with a 10-mg/m2 bolus and cisplatin 30 mg/m2 on chemotherapy days 1, 2, and 3
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Etoposide at maximum-tolerated dose (MTD) of 25 mg/m2/d
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Etoposide with Css greater than 1 microgram/mL
Number of subjects: 30
Study: 2488361

Group type: EXPERIMENTAL
Intervention: Y connector disinfectant system (Amuchina, Italy)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard systems (Baxter Systems II & III)
Number of subjects: 124
Study: 4741606

Group type: EXPERIMENTAL
Intervention: Digitalis
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (no digitalis)
Number of subjects: 22
Study: 31419694

Group type: EXPERIMENTAL
Intervention: IDT for 5 days with bandages + manual lymphatic drainage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IDT with bandages + manual lymphatic drainage + Cellu M6 for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: bandages + Cellu M6 for 5 days
Number of subjects: 0
Study: 28864147

Group type: EXPERIMENTAL
Intervention: BMP‐2/hydroxyapatite
Number of subjects: 20

Group type: COMPARATOR
Intervention: BDX
Number of subjects: 20
Study: 25742538

Group type: EXPERIMENTAL
Intervention: Poor sleep quality
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Suboptimal sleep duration
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Lower work sitting time
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Engaging in three risky lifestyle behaviors
Number of subjects: 710
Study: 23270495

Group type: EXPERIMENTAL
Intervention: Three-visit asthma service
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Four-visit asthma service
Number of subjects: 570
Study: 21530036

Group type: EXPERIMENTAL
Intervention: DOPPS Practice Monitor (DPM)
Number of subjects: 145
Study: 20088174

Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids
Number of subjects: 80

Group type: COMPARATOR
Intervention: No antenatal corticosteroids (Control)
Number of subjects: 80
Study: 16720886

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 36
Study: 15547161

Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 9193
Study: 10959912

Group type: EXPERIMENTAL
Intervention: Recombinant human deoxyribonuclease (rhDNase)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 9104564

Group type: EXPERIMENTAL
Intervention: Natural human interferon-alpha (nHuIFN alpha) 50 units
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Natural human interferon-alpha (nHuIFN alpha) 150 units
Number of subjects: 32

Group type: COMPARATOR
Intervention: Natural human interferon-alpha (nHuIFN alpha) placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Natural human interferon-alpha (nHuIFN alpha) 450 units
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control horses
Number of subjects: 32
Study: 1301491

Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 150

Group type: COMPARATOR
Intervention: Flurbiprofen
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sodium Diclofenac
Number of subjects: 150
Study: 3895034

Group type: EXPERIMENTAL
Intervention: Lisuride
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 28480692

Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage (MLD) for 30 minutes
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Local Cryotherapy (CRY) for 30 minutes
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rest (RST) for 30 minutes
Number of subjects: 30
Study: 28112691

Group type: EXPERIMENTAL
Intervention: L3‐based probiotic formula (iNatal®)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (279 pregnant women in 2015 and 892 pregnant women in 2013 and 2014)
Number of subjects: 127
Study: 24742300

Group type: EXPERIMENTAL
Intervention: Face-to-face guidance strategy (4 contacts)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: E-guidance strategy (13 contacts)
Number of subjects: 12
Study: 23292287

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Pioglitazone + Resistance training (RT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: No Resistance training (RT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo + No Resistance training (RT)
Number of subjects: 88
Study: 20620624

Group type: EXPERIMENTAL
Intervention: Fractal analysis of airway collapsibility
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (17 control subjects)
Number of subjects: 42
Study: 19140644

Group type: EXPERIMENTAL
Intervention: Extensive working memory practice on a spatial working memory task for 45 days, approximately 15 minutes per day.
Number of subjects: 2

Group type: COMPARATOR
Intervention: No intervention (no-contact control groups).
Number of subjects: 2
Study: 16493451

Group type: EXPERIMENTAL
Intervention: Exercise (E)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 16
Study: 14648264

Group type: EXPERIMENTAL
Intervention: 0.23 mJ/mm(2) energy flux density
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.42 mJ/mm(2) energy flux density
Number of subjects: 80
Study: 10433587

Group type: EXPERIMENTAL
Intervention: Chloroquine (300 mg weekly) + Primaquine (30 mg daily)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 7723545

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 109

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 109
Study: 2200299

Group type: EXPERIMENTAL
Intervention: Lignocaine 20 mg pretreatment, followed by induction with propofol plus saline 2 ml
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Lignocaine 40 mg pretreatment, followed by induction with propofol plus saline 2 ml
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Saline pretreatment, followed by induction with propofol plus lignocaine 20 mg
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Saline pretreatment, followed by induction with propofol plus lignocaine 40 mg
Number of subjects: 103

Group type: COMPARATOR
Intervention: Saline pretreatment, followed by induction with propofol plus saline 2 ml
Number of subjects: 103
Study: 7389253

Group type: EXPERIMENTAL
Intervention: 10 mg indacrinone alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg indacrinone + 2.5 mg amiloride
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg indacrinone + 5 mg amiloride
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg indacrinone
Number of subjects: 12
Study: 30883904

Group type: EXPERIMENTAL
Intervention: Late evening snacks (LES)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 341
Study: 27564775

Group type: EXPERIMENTAL
Intervention: Thymopentin (2 mg per day, 15 days, three courses in total)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Regular therapy with thymopentin
Number of subjects: 96

Group type: COMPARATOR
Intervention: Regular therapy (control group)
Number of subjects: 96
Study: 25260193

Group type: EXPERIMENTAL
Intervention: Disclaimer on airbrushed thin ideal images
Number of subjects: 48

Group type: COMPARATOR
Intervention: Neutral sentence
Number of subjects: 48

Group type: COMPARATOR
Intervention: No text
Number of subjects: 48
Study: 23030241

Group type: EXPERIMENTAL
Intervention: SRP plus 1.2% ATV
Number of subjects: 60

Group type: COMPARATOR
Intervention: SRP plus placebo gel
Number of subjects: 60
Study: 21723205

Group type: EXPERIMENTAL
Intervention: Medial-temporal atrophy (MTA)
Number of subjects: 1349

Group type: EXPERIMENTAL
Intervention: White matter hyperintensities (WMH)
Number of subjects: 1349

Group type: EXPERIMENTAL
Intervention: Cerebral atrophy (CA)
Number of subjects: 1349

Group type: EXPERIMENTAL
Intervention: MRI infarcts
Number of subjects: 1349

Group type: EXPERIMENTAL
Intervention: MTA and WMH
Number of subjects: 1349

Group type: EXPERIMENTAL
Intervention: WMH
Number of subjects: 1349
Study: 19893824

Group type: EXPERIMENTAL
Intervention: Written invitation to attend a case finding appointment with the practice nurse, including spirometry
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 400
Study: 16501408

Group type: EXPERIMENTAL
Intervention: Lotrafilcon A lenses (daily wear)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Balafilcon A lenses (daily wear)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lotrafilcon A lenses (continuous wear)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Balafilcon A lenses (continuous wear)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (non-contact lens wearers)
Number of subjects: 45
Study: 15142868

Group type: EXPERIMENTAL
Intervention: Stringent environmental control (active)
Number of subjects: 251

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 251
Study: 11712772

Group type: EXPERIMENTAL
Intervention: Web-based technology for clinical trial management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web-based software for site training, study documentation, subject recruitment, randomization, medication dispensing, and management procedures
Number of subjects: 0
Study: 9520963

Group type: EXPERIMENTAL
Intervention: Intensive follow-up protocol (multiple attempts via mail and telephone)
Number of subjects: 1453

Group type: EXPERIMENTAL
Intervention: Economic vouchers to offset out-of-pocket expenses
Number of subjects: 1453

Group type: EXPERIMENTAL
Intervention: Intensive follow-up plus voucher condition
Number of subjects: 1453

Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 1453
Study: 7999596

Group type: EXPERIMENTAL
Intervention: Etretinate treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 26
Study: 2626514

Group type: EXPERIMENTAL
Intervention: Fluphenazine (mixed D1/D2 dopamine antagonist)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study: 776193

Group type: EXPERIMENTAL
Intervention: Diazepam 0.3 mg/kg i.v. with food intake at 3 hours post-injection
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Diazepam 0.3 mg/kg i.v. with food intake at 7 hours post-injection
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Charcoal ingestion in six subjects
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Diazepam 0.15 mg/kg i.v. with rapid injection
Number of subjects: 13
Study: 6785095

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 40 microgram/kg via 30 min i.v. infusion
Number of subjects: 18
Study: 29732932

Group type: EXPERIMENTAL
Intervention: Dietary counseling efforts
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Technology-based interventions
Number of subjects: 30
Study: 30153839

Group type: EXPERIMENTAL
Intervention: Community-based interventions including economic support to families, payment of school fees, pocket money for girls, youth club and community meetings on reproductive health.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integration of adolescent sexual reproductive health and rights (SRHR) interventions into community health systems.
Number of subjects: 0
Study: 26974423

Group type: EXPERIMENTAL
Intervention: FAST treatment (20 mL/kg of crystalloid over 10 min)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: SLOW treatment (20 mL/kg of crystalloid over 30 min)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: FAST treatment
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: SLOW treatment
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Both FAST and SLOW treatments
Number of subjects: 9
Study: 25363189

Group type: EXPERIMENTAL
Intervention: Vitamin B1 (100 mg/day)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Fish oil (500 mg/day)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Both Vitamin B1 and Fish oil
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 22267420

Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg daily before bedtime for 30 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19895779

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 1452
Study: 17490746

Group type: EXPERIMENTAL
Intervention: Initial medical therapy
Number of subjects: 607

Group type: COMPARATOR
Intervention: Initial trabeculectomy
Number of subjects: 607
Study: 15235913

Group type: EXPERIMENTAL
Intervention: Practiced with one hand
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Practiced with two hands
Number of subjects: 0
Study: 12399283

Group type: EXPERIMENTAL
Intervention: MCT group (37% MCT, 63% LCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: LCT group (100% LCT)
Number of subjects: 0
Study: 10453964

Group type: EXPERIMENTAL
Intervention: 300-mg abacavir hemisulfate tablet (oral)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 300-mg abacavir hemisulfate tablet with food
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: abacavir (various formulations)
Number of subjects: 24